Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.

Autor: Ziu M; Department of Neurosurgery, Inova Neurosciences, Inova Health System, Fairfax, VA, USA. mateo.ziu@gmail.com., Halasz LM; Departments of Radiation Oncology and Neurological Surgery, University of Washington/ Fred Hutch Cancer Center, Seatle, WA, USA., Kumthekar PU; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., McGranahan TM; Division of Hematology and Oncology, Scripps Cancer Center, San Diego, CA, USA., Lo SS; Department of Radiation Oncology and Neurological Surgery, University of Washington/Fred Hutch Cancer Center, Seattle, WA, USA., Olson JJ; Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.

Publikováno v: Journal of neuro-oncology [J Neurooncol] 2024 Nov 20. Date of Electronic Publication: 2024 Nov 20.

Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease: A Phase 1 Nonrandomized Controlled Trial.

Autor: Ahmed KA; Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida., Kumthekar PU; Department of Neuro-Oncology, Northwestern University, Chicago, Illinois., Pina Y; Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida., Kim Y; Department of Biostatistics, Moffitt Cancer Center, Tampa, Florida., Vogelbaum MA; Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida., Han HS; Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida., Forsyth PA; Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida.; Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Jul 01; Vol. 10 (7), pp. 984-986.

A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT -methylated malignant glioma.

Autor: Driscoll RK; Department of Neurological Surgery, University of Chicago Medicine, Chicago, Illinois, USA., Lyne SB; Department of Neurological Surgery, University of Chicago Medicine, Chicago, Illinois, USA., Voce DJ; Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Maraka S; Department of Neurology and Rehabilitation, University of Illinois at Chicago, Chicago, Illinois, USA., Gondi V; Proton Therapy Center and Northwestern Medicine Cancer Center, Warrensville, Illinois, USA., Chmura SJ; Department of Radiation and Cellular Oncology, University of Chicago Medicine, Chicago, Illinois, USA., Dixit KS; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Kumthekar PU; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Karrison TG; Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA., Pytel P; Department of Pathology, University of Chicago Medicine, Chicago, Illinois, USA., Collins JM; Department of Radiology, University of Chicago Medicine, Chicago, Illinois, USA., Stupp R; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.; Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Merrell RT; NorthShore University Health System, Evanston, Illinois, USA., Lukas RV; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Yamini B; Department of Neurological Surgery, University of Chicago Medicine, Chicago, Illinois, USA.

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2024 Feb 01; Vol. 6 (1), pp. vdae014. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Autor: Nassiri F; Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Patil V; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Yefet LS; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Singh O; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Liu J; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Dang RMA; Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA., Yamaguchi TN; Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA., Daras M; Division of Neuro-oncology, University of California San Francisco, San Francisco, CA, USA., Cloughesy TF; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Colman H; Huntsman Cancer Institute and Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA., Kumthekar PU; Department of Neurology, Division of Neuro-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Chen CC; Department of Neurosurgery, University of Minnesota, Minneapolis, MI, USA., Aiken R; Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA., Groves MD; Department of Neurology, Texas Oncology, Austin, TX, USA., Ong SS; Division of Neuro-Oncology, Department of Neurology, the Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Ramakrishna R; Department of Neurological Surgery, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA., Vogelbaum MA; Department of Neuro-Oncology, Neuro-Oncology Program, Moffitt Cancer Center, Tampa, FL, USA., Khagi S; Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Kaley T; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Melear JM; Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA., Peereboom DM; The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA., Rodriguez A; Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AK, USA., Yankelevich M; Department of Pediatrics, University of Michigan, Ann Arbor Beaumont Children's Hospital, Royal Oak, MI, USA., Nair SG; Lehigh Valley Topper Cancer Institute, Allentown, PA, USA., Puduvalli VK; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Aldape K; Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA., Gao A; Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada., López-Janeiro Á; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain., de Andrea CE; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain., Alonso MM; Navarra Institute for Health Research (IdISNA), Pamplona, Spain.; Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.; Program of Solid Tumors, Center for the Applied Medical Research (CIMA), Pamplona, Spain., Boutros P; Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA., Robbins J; DNATrix Inc., Carlsbad, CA, USA., Mason WP; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Sonabend AM; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Stupp R; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Fueyo J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gomez-Manzano C; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lang FF; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zadeh G; Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.; Department of Surgery, University of Toronto, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.

Publikováno v: Nature medicine [Nat Med] 2023 Jun; Vol. 29 (6), pp. 1370-1378. Date of Electronic Publication: 2023 May 15.

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).

Autor: Galanis E; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Anderson SK; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, USA., Twohy E; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, USA., Butowski NA; Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA., Hormigo A; Department of Neurology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, New York, USA., Schiff D; Department of Neurology, University of Virginia Health System, Charlottesville, Virginia, USA., Omuro A; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Jaeckle KA; Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA., Kumar S; Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Kaufmann TJ; Department of Neuroradiology, Mayo Clinic, Rochester, Minnesota, USA., Geyer S; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, USA., Kumthekar PU; Northwestern Medicine, Lou and Jean Malnati Brain Tumor Institute, Chicago Illinois, USA., Campian J; Washington University School of Medicine, Siteman Cancer Center, St. Louis, Missouri, USA., Giannini C; Mayo Clinic, Rochester, Minnesota, USA., Buckner JC; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA.

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2022 Apr 04; Vol. 4 (1), pp. vdac041. Date of Electronic Publication: 2022 Apr 04 (Print Publication: 2022).